Introduction {#S0001}
============

Antiphospholipid syndrome (APS) is diagnosed when a patient meets at least one clinical and one laboratory criterion. The clinical criteria are (1) one or more clinical episodes of arterial, venous, or small vessel thrombosis in any tissue or organ confirmed by imaging or histopathology or (2) pregnancy morbidity. The laboratory criteria, all of which involve the presence of antiphospholipid (aPL) antibody, are (1) positive lupus anticoagulant (LA) antibody, (2) moderate to high levels of isotype IgG or IgM anticardiolipin (aCL) antibody, or (3) isotype IgG or IgM anti-beta-2 glycoprotein I (anti-β~2~GPI) antibody on at least two occasions at least 12 weeks apart.[@CIT0001]--[@CIT0007] In a review by Cervera,[@CIT0004] the estimated annual incidence of APS was 5 new cases per 100,000 people, and its prevalence increased with age. We herein present a case involving a very young patient with catastrophic APS (CAPS) who developed multiple thromboembolic events and positive LA antibodies.

Case report {#S0002}
===========

A 12-year-old Thai boy first presented to a local hospital with swelling and pain in both legs. Computed tomography angiography (CTA) revealed acute total occlusion of the right mid-femoral artery and left popliteal artery, pulmonary embolism (PE) in the left inferior pulmonary vein, and left renal vein thrombosis. He was treated by surgical embolectomy; however, his limb ischemia did not resolve, and he underwent bilateral limb amputation.

A laboratory investigation revealed LA antibody positivity. The protein C level, protein S level, antithrombin activity, homocysteine level, aCL antibody level, anti-β~2~GPI antibody level, factor VIII activity, and lipoprotein(a) level were within the reference range. An autoimmune study revealed normal levels of anti-double-stranded DNA antibodies, anti-Sm antibodies, and complements. Therefore, CAPS was suspected. The patient was treated with plasmapheresis for 5 days, pulse methylprednisolone for 3 days, intravenous immunoglobulin at a dose of 2 g/kg, and standard heparin. One month after the treatment, CTA showed a slightly decreased thrombus size in the renal vein and newly developed thrombosis in the right inferior pulmonary vein and right atrium. He then continued treatment with low-molecular-weight heparin and prednisolone. Three months later, he developed dyspnea and orthopnea. An echocardiogram revealed a 3.6-×3.4-cm thrombus in the right atrium, and CTA showed bilateral renal artery stenosis. The thrombus was surgically removed. Pulse methylprednisolone, milrinone, dobutamine, and standard heparin were administered.

After the patient showed clinical improvement, the medications were changed to digoxin and enoxaparin. The patient then was referred to Ramathibodi Hospital for further treatment and diagnosis. At admission, physical examination revealed tachycardia and an oxygen saturation of 97%. CTA showed a 2.7-×4.9-×4.0-cm thrombus in the right atrium protruding into the right ventricle and acute PE in the subsegmental arteries. Pulse methylprednisolone, cyclophosphamide, intravenous immunoglobulin, and heparin were given. Further investigation of both perinuclear and cytoplasmic antineutrophil cytoplasmic antibodies was negative. Ten days after treatment, the patient's clinical symptoms improved. He continued treatment with enoxaparin, aspirin, prednisolone, and sildenafil for pulmonary hypertension. His anti-factor Xa level was within the therapeutic range at 0.9 to 1.0 IU/dL. Four months later, after the fourth course of cyclophosphamide, he developed dyspnea and was found to have pericardial effusion caused by pulmonary hypertension. Pericardiocentesis was performed. CTA revealed a new thrombus in the pulmonary artery at the right lower segment and persistence of the thrombus in the right atrium. During hospitalization, he developed progressive dyspnea secondary to PE and pulmonary hypertension and subsequently died of heart failure.

Autopsy revealed a 22.5-cm-long surgical wound in the chest wall from the sternotomy. Fibrinous pericarditis ([Figure 1A](#F0001){ref-type="fig"}) with about 30 mL of serosanguinous-type pericardial effusion was detected in the pericardial cavity. A 5.5-×4.0-×4.0-cm intracardiac thrombus was observed in the right atrial chamber; the thrombus was attached to the posterior leaflet of the tricuspid valve and extended into the right ventricular chamber ([Figure 1B](#F0001){ref-type="fig"}). Microscopic examination revealed an organized thrombus ([Figure 1C](#F0001){ref-type="fig"}) with endocardial fibrosis. A pulmonary thromboembolus was grossly demonstrated in the branch of the left pulmonary artery ([Figure 2A](#F0002){ref-type="fig"}). Microscopic examination revealed the recanalized phase of the thrombus with the organizing phase at the periphery ([Figure 2B](#F0002){ref-type="fig"} and [C](#F0002){ref-type="fig"}). Numerous recent thrombi were also observed in the capillaries and small arterioles of the bilateral lungs and kidneys. However, no evidence of vasculitis, infection, or malignancy was found in any organs. Figure 1Heart with intracardiac thrombus. (**A**) Fresh specimen, anterior aspect. External appearance of the heart with fibrinous pericarditis. (**B**) Ten percent neutral formalin-fixed specimen, right lateral aspect. Opening of the right atrial chamber showed an intracardiac thrombus (asterisk) that extended into the right ventricular chamber. (**C**) Histopathological examination of the intracardiac thrombus showed a recanalized and organized (asterisk) thrombus. Hematoxylin and eosin; original magnification, 20×.Figure 2Left lung with pulmonary thromboembolus. (**A**) Fresh specimen. Red-white thrombus (arrowhead) in the descending branch of the left pulmonary artery. (**B, C**) Histopathological features of pulmonary thromboembolus showing organized (asterisk) and recanalized thrombus. Hematoxylin and eosin; original magnification, 20× in b and 100× in c.

Discussion and conclusion {#S0003}
=========================

The diagnosis of APS is based on the presence of vascular thrombosis or recurrent pregnancy loss and persistent positivity for aPL, LA, aCL, or anti-β~2~GPI antibodies on two or more occasions at least 12 weeks apart. APS without an associated condition is called primary APS. Vascular involvement in patients with APS presents with various features such as PE, lower extremity venous thrombosis, stroke, and intestinal infarction.[@CIT0004] In their 10-year study of a large cohort of patients with APS, Cervera et al[@CIT0008] found that the most common thrombotic events were stroke, transient ischemic attack, deep vein thrombosis, and PE. Intracardiac thrombus is an uncommon finding in patients with APS.[@CIT0009]--[@CIT0015] CAPS, also known as Asherson's syndrome, is a rare and severe form of APS defined as a rapidly progressive thromboembolic disease involving three or more organs. The disease mainly affects small vessels supplying organs and presents within a short period of time (usually \<1 week).[@CIT0003],[@CIT0008],[@CIT0016] Its prevalence is \<1% of all APS cases.[@CIT0004],[@CIT0016]--[@CIT0018]

Although the pathogenesis of APS is poorly understood, a "two-hit theory" has been proposed as the mechanism underlying APS. This theory suggests that aPL antibodies act through many possible routes to create the necessary conditions for thrombosis, acting as the "first hit": (1) aPL antibodies bind to β~2~GPI expressed on the surface of endothelial cells, inducing the cells to change to a procoagulant and proinflammatory phenotype. (2) aPL antibodies cause upregulation of platelet tissue factor expression by endothelial cells and monocytes, endothelial leukocyte adhesion, cytokine secretion, and prostaglandin E2 synthesis, all of which are processes that promote inflammation. (3) aPL antibodies bind to phospholipid-binding proteins on platelets, promoting platelet aggregation. (4) aPL antibodies inhibit fibrinolysis, binding of annexin A5 to anionic structures, and anticoagulant activity. These conditions alone are not sufficient to induce thrombosis, but a "second hit" that causes complement activation, such as that induced by infection, pregnancy, obesity, diabetes, or endothelial injury, is theorized to cause thrombus formation.[@CIT0019]--[@CIT0021]

Our patient had a history of vascular thrombosis (right femoral and left popliteal arteries, PE of the pulmonary vein, and left renal vein thrombosis) and a huge intracardiac thrombus in the right atrium extending into the right ventricle. An LA test was not performed 12 weeks later because of continued heparin treatment. Although he underwent surgical thrombus removal, he died of PE and heart failure. There was no evidence of a secondary cause of APS, such as systemic lupus erythematosus or autoimmune hemolytic anemia. Therefore, the patient was considered to have had primary APS classified as CAPS, with multiple vascular thromboses including intracardiac thrombus, a rare complication of APS. The exact mechanism underlying the development of intracardiac thrombus is not understood, but such thrombus formation can cause pulmonary and systemic embolic events. If the thrombus is small, it may be misinterpreted as a vegetation or intracardiac tumor such as an atrial myxoma by echocardiographic examination. Thus, the pathologist should be aware of these conditions as differential diagnoses when a surgical specimen from an intracardiac tumor is received.[@CIT0009],[@CIT0010] Although this condition is life-threatening, it is treatable. Management usually requires surgical thrombus removal. However, embolic events may recur; thus, intensive anticoagulation treatment and immunosuppressive therapies are required. The decision to perform surgical intracardiac thrombus removal in patients with APS must be made carefully because of the hemorrhagic risk factors accompanying APS and the risk of further thrombotic events and postoperative complications.[@CIT0022],[@CIT0023]

One literature review summarized nine patients with APS with intracardiac thrombi ([Table 1](#T0001){ref-type="table"}). Most of these patients were women aged 30 to 40 years.[@CIT0009]--[@CIT0015] The most common location of the intracardiac thrombus was the right atrial chamber; in some cases, however, the thrombus was found in the left atrium and left ventricle.[@CIT0010],[@CIT0012],[@CIT0014] One of these patients was a female adolescent who had APS associated with underlying systemic lupus erythematosus.[@CIT0014] As mentioned above, intracardiac thrombi are treatable by surgical intervention or anticoagulation therapy. Most cases are resolved with a good clinical outcome, and recurrent events rarely occur. In the present case, however, PE recurred after resolution of the clinical symptoms, resulting in the patient's death. The postmortem thrombus was organized and showed no evidence of infection or malignant cells. The endocardium showed various degrees of endocardial fibrosis.Table 1Summary of patients with antiphospholipid syndrome with intracardiac thrombusCase No.Ref.SexAge, yearsPresentationaPL testHeart chamberTreatmentOutcomePathologic diagnosis**1**Basso et al (2005)[@CIT0011]F43SyncopeLA+Right atriumSurgical removalResolvedOrganized thrombus**2**Lim et al (2004)[@CIT0013]F40Dyspnea and hemoptysisaCL+Right atriumSurgical removalResolvedMural thrombus with endocardial fibrosis**3**Marie et al (2003)[@CIT0012]F44Left hemiparesisLA+, aCL+, anti-β~2~GPI+Left atriumAnticoagulantResolvedNA**4**Marie et al (2003)[@CIT0012]M41Limb ischemiaLA+, aCL+, anti-β~2~GPI+Left atriumAnticoagulantResolvedNA**5**Cianciulli et al (2009)[@CIT0010]M39Left hemiparesis and peripheral embolismLA+Left ventricleSurgical removalResolvedThrombus with minimal vascular and perivascular inflammation**6**Cianciulli et al (2008)[@CIT0009]F37Progressive dyspneaLA+Right atriumSurgical removalRecurrenceOrganized thrombus**7**Plein et al (1996)[@CIT0014]F35Fever with acute dyspneaaCL+Right atriumSurgical removalResolvedThrombus**8**Plein et al (1996)[@CIT0014]F13Apical systolic murmur with severe thrombocytopeniaaCL+Left ventricleSurgical removalResolvedThrombus**9**Ye et al (2005)[@CIT0015]F22DyspneaLA+Right atriumSurgical removalResolvedPartial organized necrotic thrombus with endocardial fibrosis**10**Present caseM12Limb ischemia with chest painLA+Right atrium and right ventricleSurgical removalResolved with recurrenceRecent with organized thrombus[^1]

In conclusion, we have herein reported a case involving a 12-year-old Thai boy with CAPS diagnosed by thromboembolic events in several organs, including the extremities (history of bilateral lower limb amputation), lungs, renal vein, right ventricle, and right atrial chamber presenting with recurrent intracardiac thrombosis and pulmonary thromboembolism. The patient died of cardiac tamponade caused by clinically silent pericardial effusion followed by cardiogenic heart failure. Intracardiac thrombosis and pulmonary thromboembolism were confirmed by postmortem examination.

To our knowledge, the present report describes the youngest patient with APS with an intracardiac thrombus in both the right atrium and right ventricle. Despite the rarity of pediatric APS, physicians should keep in mind the possibility of this APS manifestation to ensure timely administration of effective treatments.
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[^1]: **Abbreviations:** F, female; M, male; Ref., reference; NA, not available; LA, lupus anticoagulant; aCL, anticardiolipin; anti-β~2~GPI, anti-beta-2 glycoprotein I.
